EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

Yosuke Kitagawa, Ami Kobayashi, Daniel P Cahill, Hiroaki Wakimoto, Shota Tanaka

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024

DOI: 10.1016/j.bbcan.2024.189102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024. Verfasst von Yosuke Kitagawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 02114 Boston, MA, USA; Translational Neuro-Oncology Laboratory, M…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Brain Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 174 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Uehara Memorial Foundation, Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas with Isocitrate dehydrogenase (IDH) mutation represent a discrete category of primary brain tumors with distinct and unique characteristics, behaviors, and clinical disease outcomes. IDH mutations lead to aberrant high-level production of the oncometabolite D-2-hydroxyglutarate (D-2HG), which act as a competitive inhibitor of enzymes regulating epigenetics, signaling pathways, metabolism, and various other processes. This review summarizes the significance of IDH mutations, resulting upregulation of D-2HG and the associated molecular pathways in gliomagenesis. With the recent finding of clinically effective IDH inhibitors in these gliomas, this article offers a comprehensive overview of the new era of innovative therapeutic approaches based on mechanistic rationales, encompassing both completed and ongoing clinical trials targeting gliomas with IDH mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseGliomaMutationBrain NeoplasmsHumansEnzyme InhibitorsGlutaratesAntineoplastic AgentsAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

D2-hydroxyglutarate (D2-HG)GliomaIsocitrate dehydrogenase (IDH)

Substanzen

Isocitrate DehydrogenaseEnzyme InhibitorsGlutaratesAntineoplastic Agentsalpha-hydroxyglutarate

Autor:innen und Institutionen

  • Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 02114 Boston, MA, USA; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, 02114 Boston, M…
  • Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 02115 Boston, MA, USA.
  • Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 7008558, Okayama, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Uehara Memorial Foundation
  • Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering

Zitieren

APA

Kitagawa, Y., Kobayashi, A., Cahill, D. P., Wakimoto, H., & Tanaka, S. (2024). Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2024.189102

Vancouver

Kitagawa Y, Kobayashi A, Cahill DP, Wakimoto H, Tanaka S. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024. doi:10.1016/j.bbcan.2024.189102

BibTeX
@article{Kitagawa2024,
  author = {Kitagawa, Yosuke and Kobayashi, Ami and Cahill, Daniel P and Wakimoto, Hiroaki and Tanaka, Shota},
  title = {Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2024},
  doi = {10.1016/j.bbcan.2024.189102}
}
Kostenlos starten →